A proof-of-concept study on the use of a fluorescein-based $^{18}$F-tracer for pretargeted PET

Hugo Helbert$^{1,2}$, Emily M. Ploeg$^4$, Douwe F. Samplonius$^4$, Simon N. Blok$^2$, Ines F. Antunes$^2$, Verena I. Böhmer$^{1,2}$, Gert Luurtsema$^2$, Rudi A. J. O. Dierckx$^2$, Ben L. Feringa$^1$, Philip H. Elsinga$^2$, Wiktor Szymanski$^3$*, and Wijnand Helfrich$^4$

Abstract

Background: Pretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-lived PET isotopes, while reducing the irradiation dose caused by traditional $^{89}$Zr-labelled antibodies. In this work, we demonstrate proof of concept of a novel 'two-step' immuno-PET pretargeting approach, based on bispecific antibodies (bsAbs) engineered to feature dual high-affinity binding activity for a fluorescein-based $^{18}$F-PET tracer and tumor markers.

Results: A copper(I)-catalysed click reaction-based radiolabeling protocol was developed for the synthesis of fluorescein-derived molecule $[^{18}$F$]$TPF. Binding of $[^{18}$F$]$TPF on FITC-bearing bsAbs was confirmed. An in vitro autoradiography assay demonstrated that $[^{18}$F$]$TPF could be used for selective imaging of EpCAM-expressing OVCAR3 cells, when pretargeted with EpCAMxFITC bsAb. The versatility of the pretargeting approach was showcased in vitro using a series of fluorescein-binding bsAbs directed at various established cancer-associated targets, including the pan-carcinoma cell surface marker EpCAM, EGFR, melanoma marker MCSP (aka CSPG4), and immune checkpoint PD-L1, offering a range of potential future applications for this pretargeting platform.

Conclusion: A versatile pretargeting platform for PET imaging, which combines bispecific antibodies and a fluorescein-based $^{18}$F-tracer, is presented. It is shown to selectively target EpCAM-expressing cells in vitro and its further evaluation with different bsAbs demonstrates the versatility of the approach.

Keywords: ImmunoPET, Pretargeting, $[^{18}$F$]$Fluorescein, Bispecific antibody, $[^{18}$F$]$TPF

Introduction

Driven by the established broad clinical applicability of $^{18}$F-FDG scans (Sheikhhbahaei et al. 2017), positron emission tomography (PET) has become a leading technique for imaging of aberrant metabolic processes in the human body (Unterrainer et al. 2020). Diagnostic PET imaging aims to visualize disease-specific processes and/or markers using an appropriate selective radiotracer (Kilbourn et al. 2021). Typically, a PET
radiotracer is a small target-seeking molecule equipped with a short-lived $\beta^+$-emitting radioisotope. Amongst suitable isotopes for PET imaging, $^{18}$F is routinely used due of its convenient half-life (109.8 min) and low positron energy ($E_{\text{mean}} = 0.250$ MeV), which ensures high image resolution (Conti and Eriksson 2016). Considering the half-life of radionuclides, PET-tracers carrying them are required to possess compatible pharmacokinetics properties, i.e. fast biodistribution and accumulation in the tissue of interest, to enable optimal selective imaging after minutes up to few hours post-injection. Therefore, large target-seeking molecules, such as antibodies, constitute far from ideal candidates for the construction of PET tracers. Typically, antibodies, while offering selective, efficient, rapid, and sustained target binding, have impractically long circulation times of up to days, which limits their use in immuno-PET tumor imaging, particularly with respect to difficult-to-penetrate solid tumours. While the long half-life of $^{89}$Zr (78.4 h) has been successfully used for direct labelling of antibodies (Heskamp et al. 2017; McKnight and Viola-Vilegas et al. 2018), this strategy suffers from major impediments related to the long circulating time of the $^{89}$Zr-PET probe, notably the high irradiation dose received by healthy tissues (Jauw et al. 2016; Dewulf et al. 1868).

To overcome the limitations of using conventional antibodies for immuno-PET imaging, promising pretargeting approaches have been developed (Altai et al. 2017; Bailly et al. 2017; van de Watering et al. 2014; Marquez and Lapi 2016). Typically, pretargeting involves the injection into the circulation of the patient with an unlabelled, tumour-seeking, bi-functional antibody, which is given time (typically 24–48 h) to reach its optimal target binding at acceptable off-target background levels. Subsequently, a low molecular weight tracer is injected that is labelled with a positron-emitting radioligand for PET imaging, equipped with an inert binding tag (hapten) that can be efficiently captured by bifunctional antibodies that have accumulated at the site(s) of the tumour(s), whereas any unbound tracer rapidly clears from the circulation. Importantly from the application point of view, it is conceivable to administer the bispecific antibody outside of the specialized imaging department, after which the $^{18}$F-labeled agent is administered at the hospital site, shortly before the imaging procedure.

Pretargeting strategies notably exploit the strong biotin-streptavidin interaction (Weber et al. 1989; Hnatowich et al. 1987; Rusckowski et al. 1997; Goldenberg et al. 2006) and, in more recent examples, take advantage of the biorthogonal reaction of tetrazines with a trans-cyclooctenes (Rossin et al. 2010; Rossin and Robillard 2014; Rondon and Degoul 2020). Alternatively, pretargeting can effectively be achieved in vivo using so-called bispecific antibodies (bsAbs) (Molema et al. 2000; Lütje et al. 2014; Yu et al. 2017). BsAbs represent a unique class of rapidly emerging therapeutics that combine two target functionalities into one recombinant antibody-based molecule. In this respect, bsAbs have been engineered in which the primary binding domains are directed towards a preselected cancer-associated cell membrane marker and the secondary binding domains towards an inert small molecule (e.g. hapten). Upon selective binding and accumulation of the bsAb at the tumour site(s), the secondary binding domains are available for capturing a haptenylated compound of choice. Previously, pretargeting approaches have been described in which the tumour-directed bsAbs showed second specificity towards a chelator incorporated with a radiometal (Le Doussal et al. 1990), or
Results and discussion

Design and synthesis

Here, we present a proof-of-concept for the use of a novel pretargeting platform, for PET imaging, combining bispecific antibodies (bsAbs) and a fluorescein-based $^{18}$F-PET tracer (Fig. 1). We selected fluorescein as a particularly suitable hapten for this approach, since it is an established, non-toxic, FDA-approved agent that is routinely used in angiography and that has confirmed low immunogenicity (Lumbroso et al. 2014). To construct a versatile platform for fluorescein-based pretargeted immuno-PET, we equipped bsAb with affinity-maturated scFv antibody fragments ($K_D = 1.8 \times 10^{-10} \text{M}$) that potently bind to fluorescein and several derivatives thereof, including carboxy-fluorescein, fluorescein isothiocyanate (FITC), and Oregon green, and retain the binding potency even when these are conjugated to other compounds (Schwesinger et al. 2000; He et al. 2017).

For the design of the fluorescein-based, $^{18}$F-bearing tracer, an alkyne moiety was introduced to the fluorescein molecule, enabling rapid labelling using copper(I) azide-alkyne cycloaddition (CuAAC) reaction (Meyer et al. 2016; Gill et al. 2011), to link the modified fluorescein with a fluorinated polyethylene glycol (PEG) chain as shown in Scheme 1 (Sirion et al. 2007; Li et al. 2007). The choice of $^{18}$F for the PET-tracer is noteworthy as the majority of previously mentioned strategies utilize higher energy radiometals combined with bispecific antibodies (Le Doussal et al. 1990; Janevik-Ivanovska et al. 1997; Sharkey et al. 2012; Schoffelen et al. 2013).
Sharkey et al. 2012; Schoffelen et al. 2013). The reference compound, triazole-pegylated-fluorescein (TPF), was prepared first (for details of the synthesis and characterization, see Additional file 1).

**In vitro binding assessment of TPF with bsAb EpCAMxFITC**

Preliminary binding studies were performed between the non-radiolabeled TPF and the bsAb EpCAMxFITC that was engineered to have dual high-affinity binding activity for the pan-carcinoma cell surface marker EpCAM and fluorescein. Upon capture by bsAb EpCAMxFITC, the fluorescence of TPF is quenched, which enables the monitoring of the binding in real-time (Saunders et al. 2014). Titration of a TPF solution with bsAb EpCAMxFITC resulted in a significant reduction of the fluorescence signal (see Additional file 1: Figure S2). This effect was also observed when the bsAb EpCAMxFITC was first bound to EpCAM-expressing OVCAR3 cancer cells (see Additional file 1: Figure S3), indicating that TPF binds to bsAb EpCAMxFITC even at lower concentrations of bsAbs, relevant in pretargeting approaches, in this case limited by EpCAM expression. The selective binding of bsAb EpCAMxFITC to the cell surface of EpCAM-expressing OVCAR3 cancer cells was confirmed by flow cytometry (see Additional file 1: Figure S1).

**Radiolabelling of \(^{18}\text{F}\text{TPF}\)**

Next, the radiosynthesis of \(^{18}\text{F}\text{TPF}\) was developed to allow for a rapid and efficient labelling procedure (Scheme 2). \(^{18}\text{F}\)F\(^-\) (3–5 GBq) was azeotropically dried, before the addition of the tosylate precursor 4 (3 mg, 9 µmol) in MeCN. The \(^{18}\text{F}\)-fluorination was carried out for 10 min at 110 °C. The labelled azide \(^{18}\text{F}\)3 was isolated by HPLC in 56 ± 8% radiochemical yield (RCY, n = 7, see Additional file 1: Figure S4 for radio-TLC analysis and Additional file 1: Figure S4 for the HPLC analysis), concentrated in an HLB Plus Short cartridge, eluted with 1.2 mL of DMSO, and further reacted with the fluorescein alkyne 2 (1.0–1.5 mg, 2.3–3.5 µmol) in the presence of a premixed catalytic mixture containing CuSO\(_4\), sodium ascorbate and TBTA. The CuAAC reaction allowed for the synthesis of \(^{18}\text{F}\text{TPF}\) in high yields (78 ± 7% RCY, n = 8) with a molar activity of \(A_m = 27.6 ± 0.8\) TBq/mmol (n = 3), and high radiochemical purity (> 99%). The detailed labelling procedure is available in Additional file 1, together with the HPLC analysis of the reaction (Additional file 1: Figure S6) and product purity (Additional file 1: Figure S7). The in vitro stability of \(^{18}\text{F}\text{TPF}\) was evaluated indicating no measurable degradation after incubation in human plasma at 37 °C for 2 h (see Additional file 1: Figure S8).
In this study we focused exclusively on employing $[18F]TPF$ in combination with FITC-containing bsAb for pretargeting purposes. Nonetheless, capitalizing on the diverse uses of fluorescein derivatives, $[18F]TPF$ can prove to be relevant beyond this application. For example, taking advantage of the fluorescent properties of $[18F]TPF$ offers opportunities in dual-modality imaging, combining a PET signal with optical imaging (Jennings et al. 2009). Alternative applications for $[18F]TPF$ also includes the sensitive detection of cerebrospinal fluid leaks by PET imaging (Kommidi et al. 2017; Guo et al. 2019), where similar fluorescein-based 18F-PET tracers have emerged in the recent years.

**In vitro pretargeting assay with $[18F]TPF$ on EpCAM-expressing OVCAR3 cells**

The radiotracer $[18F]TPF$ was used in a radio-assay to confirm binding to bsAb EpCAMxFITC. Immobilizing of bsAb EpCAMxFITC on protein A agarose beads and comparing the uptake of $[18F]TPF$ with a similarly constructed bsAb EpCAMxMock enabled the evaluation of binding specificity. A nine-fold increase in binding was observed for the bsAb EpCAMxFITC compared with EpCAM-binding bsAb with an irrelevant second binding specificity (bsAb EpCAMxMock) (Additional file 1: Figure S9). Next, a pretargeting experiment was executed using EpCAM-expressing OVCAR3 cancer cells pretargeted (or not) with bsAb EpCAMxFITC, washed to remove any unbound antibody, and then incubated with $[18F]TPF$. After a final washing step to remove any unbound $[18F]TPF$, the radiotracer uptake was evaluated. To demonstrate EpCAM-selectivity of this approach, control experiments were performed using OVCAR3 cancer cells in which EpCAM expression was knocked out using CRISPR-Cas9 gene editing technology. Visualization and quantification of bsAb-mediated uptake of $[18F]TPF$ was performed by autoradiography of the cancer cells (Fig. 2). The low, and similar, $[18F]TPF$ uptake observed for both EpCAM$^{neg}$ and EpCAM$^{pos}$ cells that where not incubated with bsAb, confirms that $[18F]TPF$ does not bind directly to EpCAM and is not subject to unspecific uptake by cells, both being important criteria for a suitable PET-tracer. The selectivity of the EpCAMxFITC bsAb for the EpCAM and the efficiency of the washing procedure is demonstrated by the low $[18F]TPF$ uptake observed for EpCAM$^{neg}$ cells incubated with bsAb that did not show a significant difference compared with the uptake observed for EpCAM$^{neg}$ cells not incubated with this bsAb. Finally, the results of the autoradiography indicated enhanced uptake of $[18F]TPF$ by EpCAM-positive OVCAR3 cancer cells when these cells were pretargeted with bsAb EpCAMxFITC, compared to all three control groups ($n=12$, $P < 0.001$). This result indicates that $[18F]TPF$ retains...
its high affinity for the EpCAMxFITC bsAb, even when the bsAb is already engaged in binding with EpCAM, an essential indication that this approach is suitable for pretargeting of EpCAM-expressing cancer cells. These results suggest that EpCAM-selective PET tumour imaging may be achieved in a two-step pretargeting approach using bsAb EpCAMxFITC and $[^{18}F]TPF$.

**$[^{18}F]TPF$ uptake by a variety of bsAbs**

To demonstrate the versatility of our bsAb-based pretargeted immuno-PET platform, we extended our study with additional FITC-binding bsAbs, each directed at clinically relevant cancer-associated target molecules, including melanoma marker MCSP (aka CSPG4), epidermal growth factor receptor (EGFR) and immune checkpoint PD-L1. In particular, bsAb MCSPxFITC was engineered to have high affinity binding capacity for the cell surface molecule MCSP, a promising target for malignant melanoma (Kageshita et al. 1991; Jordaan et al. 2017). Analogously, bsAb EGFRxFITC was engineered to have high affinity binding capacity for EGFR, a clinically relevant cancer-associated cell surface marker that is selectively overexpressed on various difficult-to-treat carcinomas and glioma (Sun et al. 2018). Finally, we evaluated the applicability of our pretargeting strategy using bsAb PD-L1xFITC that was engineered to have high-affinity blocking capacity for the inhibitory immune checkpoint molecule PD-L1, which is frequently overexpressed in various cancer types. Imaging of PD-L1-expressing tumors may be of therapeutic value to identify cancer patients who may profit from cancer immunotherapy based on PD-L1 immune checkpoint blockade (Koopmans et al. 2019; van de Donk et al. 2020; Koopmans et al. 2018). Gratifyingly, target antigen-selective binding was observed for all the studied bsAbs. Specifically, incubation of each of these bead-immobilized bsAbs with the $[^{18}F]TPF$ radiotracer resulted in an up to four-fold increase in binding of $[^{18}F]TPF$ by the corresponding bsAb compared with control bsAb EpCAMxMock, which was not equipped with the anti-fluorescein scFv fragment responsible for $[^{18}F]TPF$ binding (Fig. 3). Noticing no significant difference in $[^{18}F]TPF$ uptake between the bsAb EpCAMxMock and the protein A agarose beads only, we can confidently exclude binding of the $[^{18}F]TPF$ independent of the anti-fluorescein scFv fragment. Importantly, there was no significant difference in $[^{18}F]TPF$ uptake for all bsAbs containing this fluorescein-binding scFv fragment, suggesting that modifying the bsAb format to direct it towards different cell surface tumor markers does not influence $[^{18}F]$
TPF binding by the anti-fluorescein scFv fragment. These results indicate the versatility of our bsAb-based two-step PET imaging approach for various tumour types using one and the same $[^{18}\text{F}]\text{TPF}$ tracer.

**Conclusion**

In conclusion, the study of a novel pretargeted immuno-PET platform based on a combination of bispecific antibodies and a $^{18}\text{F}$-fluorescein-based PET-probe showed promising results in vitro. An efficient radiolabeling protocol, exploiting copper-catalyzed click chemistry, was developed for the radiosynthesis of $[^{18}\text{F}]\text{TPF}$. The $^{18}\text{F}$-modified-Fluorescein tracer retained its affinity for FITC bsAbs and the specific uptake of $[^{18}\text{F}]\text{TPF}$ in EpCAM-overexpressing OVCAR3 cells, pretargeted with EpCAMxFITC bsAb, was confirmed by in vitro autoradiographic assays. These results should encourage further development and optimization of $[^{18}\text{F}]\text{TPF}$ for in vivo ovarian cancer imaging applications. Lastly, the versatility of the pretargeting approach was demonstrated by $[^{18}\text{F}]\text{TPF}$ capture by a series of cancer-selective bsAbs, targeting clinically relevant cancer-associated cell surface markers MSCP, PD-L1 and EGFR. We envision that this novel and versatile bsAb-based approach may prove to be useful to broaden the clinical efficacy of immuno-PET tumour imaging.

**Methods**

**General and synthetic methods**

For the general description of the materials, cell lines, methods and synthetic procedures, please see Sections 1–3 of the Additional file 1.

**Antibody production and binding assessment**

For the general description of the antibody construction, eucaryotic production and the assessment of binding and florescence quenching capacity, see Sections 4–7 of the Additional file 1.

**Radiolabeling of $[^{18}\text{F}]\text{TPF}$**

A QMA cartridge was pre-conditioned by passing 10 mL of 1.4% aq. sol. NaHCO$_3$ followed by 15 mL of deionized H$_2$O to reach pH = 7. The cartridge was then dried under argon flow. The $[^{18}\text{F}]\text{F}^-$ in enriched $[^{18}\text{O}]\text{H}_2\text{O}$ obtained from the cyclotron (typically 3–5 GBq in 1.2 mL) was passed through the dried cartridge, followed by 5 mL of air to elute most of the H$_2$O. The $[^{18}\text{F}]\text{F}^-$ remaining on the QMA was eluted, into a 4 mL conical vial, with a 1 mL solution containing 15 mg of Kryptofix K$_{222}$ in 800 μL of MeCN and 1 mg of K$_2$CO$_3$ in 200 μL H$_2$O. Solvents were removed at 115 °C under magnetic stirring and argon flow, 1 mL of anhydrous MeCN was added and evaporated to dryness. This process was repeated 3 times with 0.5 mL of anhydrous MeCN. To the azeotropically dried $[^{18}\text{F}]\text{F}^-$/K$_{222}$ mixture was added 3 mg (9 μmol) of 2-(2-(2-azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (5) in 0.5 mL of anhydrous MeCN. (NB.: The tosylate 5 was previously azeotropically dried at 100 °C by repeated addition of anhydrous MeCN and evaporation (3 × 0.5 mL)). The reaction mixture was then stirred at 110 °C for 10 min and, at the end of the reaction, was diluted with 0.5 mL of H$_2$O. The reaction mixture was then injected on HPLC (see Additional file 1: Section 8 for HPLC conditions)
the product ([18F]3) was collected (tR = 8.2 min., 56 ± 8% RCY from dry [18F]F). The collected fraction was diluted with 80 mL of H2O and concentrated in an Oasis PRiME HLB Plus Short cartridge, which was pre-conditioned with 10 mL of H2O. In the meantime, a catalytic mixture was prepared for the CuAAC reaction. First, 4 mg (20 μmol) of sodium ascorbate in 200 μL of H2O were added to 2.5 mg (10 μmol) Cu2SO4·5H2O dissolved in 100 μL of H2O. The resulting solution was pre-mixed for 5 min to obtain a dark brown solution. 5.6 mg (10.5 μmol) of TBTA in 200 μL of DMSO was added and mixed to afford a light orange solution, from which 200 μL was taken and added to a 4 mL conical vial containing 1.5 mL of fluorescein alkyne (4). [18F]3 was eluted from the HLB cartridge into the same 4 mL conical vial by passing 1.2 mL of DMSO through the HLB cartridge. The reaction mixture was stirred at 80 °C for 20 min. At the end of the reaction, 0.8 mL of H2O (containing 0.1% of formic acid) was added and the solution was purified by HPLC (see Additional file 1: Section 8 for HPLC conditions) and the [18F]TPF product was collected (tR = 23 min, 78 ± 7% RCY from eluted [18F]3). The collected fraction was diluted with 70 mL of H2O and concentrated in a pre-conditioned (10 mL of EtOH followed by 20 mL of H2O) Waters Sep-Pak Plus Light C18 cartridge. [18F]TPF was eluted from cartridge with 1 mL of EtOH and diluted with 9 mL of PBS affording typically 300–700 MBq of product. A sample was taken and submitted to UPLC measurement for QC to assess the purity and molar activity of the product. All the radio-TLC and HPLC analyses can be found in the Additional file 1: Section 8.

**Stability [18F]TPF in human serum**

In an Eppendorf tube, containing 200 μL of human serum, was added 5 μL of [18F]TPF (50 kBq) in PBS/EtOH (9/1). The mixture was shaken at 37 °C for 0, 60 and 120 min. 200 μL of MeCN was then added to induce protein precipitation. The sample was then vortexed and the supernatant was analyzed on an iTLC and compared with the initial [18F]TPF (Rf = 0.45; 10% MeOH in DCM as eluent). After exposure to a phosphor plate, the iTLC was read on an Amersham Typhoon Imager (see Additional file 1: Figure S8).

**Assessment of capacity of bead-bound bsAb EpCAMxFITC to capture [18F]TPF**

In short, 10 μg of bsAb EpCAMxFITC (or bsAb EpCAMxMock) was mixed with a slurry of 50 μl Protein A agarose beads (SinoBiological) in final volume of 500 μl PBS, and the mixture incubated at rt for 30 min. Next, the beads were pelleted by centrifugation (2500 rpm, 5 min) and washed 2 times with PBS to remove unbound bsAb. The washed beads were resuspended in 100 μL PBS, mixed with 25 μL of a [18F]TPF (0.5–1.0 MBq) solution in PBS/EtOH (9:1 vol/vol), and incubated under continuous gentle shaking at rt for 15 min. Then, PBS was added to a final volume of 500 μL, after which the beads were pelleted by centrifugation (2500 rpm, 5 min). Next, 480 μL of the supernatant solution was collected and replaced by the same volume of PBS after which the beads were pelleted again. This washing procedure was repeated 2 more times after which radioactivity associated with beads and that present in the combined supernatants were then measured using a gamma counter.
Assessment of capacity of cancer cell-bound bsAb EpCAMxFITC to capture $[^{18}\text{F}]\text{TPF}$

In short, $10 \times 10^3$ OVCAR-3 cells per well were seeded in an 8 wells permanox chamber slide (LAB-TEK, Nagle Nunc Int.), allowed to adhere, and then incubated (or not) with 10 μg of bsAb EpCAMxFITC (or bsAb EpCAMxMock) at 37 °C for 1 h. Next, the cells were washed 2 times with PBS to remove unbound bsAb and then incubated (or not) with 200 μL of 0.5–1 MBq of $[^{18}\text{F}]\text{TPF}$ in PBS (< 2% EtOH) at rt for 30 min. Subsequently, the cells were washed two times with PBS to remove unbound $[^{18}\text{F}]\text{TPF}$. Finally, the growth chamber was carefully removed, after which the glass slide with adhered cells was carefully washed with PBS and then air-dried. The dried glass slide was wrapped in aluminium foil and exposed to a phosphor plate for up to 1 h. The phosphor plate (see Section 11 of the Additional file 1) was imaged using a Amersham Typhoon Imager to record the autoradiographic images.

Abbreviations
bsAb: Bispecific antibody; CSPG4: Chondroitin sulfate proteoglycan 4; CuAAC: Copper-Catalyzed Azide-Alkyne Cycloaddition; EGFR: Epidermal growth factor receptor; EpCAM: Epithelial cell adhesion molecule; FDG: Fluorodeoxyglucose; FITC: Fluorescein isothiocyanate; HPLC: High-performance liquid chromatography; MSCP: Melanoma chondroitin sulfate proteoglycan; PD-L1: Programmed death-ligand 1; PET: Positron Emission Tomography; RCY: Radiochemical yield.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s41181-022-00155-2.

Acknowledgements
None.

Authors’ contributions
HH, SNB, VIB and WS performed the synthesis and labeling. EMP and DFS prepared the cells and the bsAbs. HH, DFS, SNB and IFA performed the binding assays. HH, BLF, PHE, WS and WH prepared the manuscript. GL, RAJOD, BLF, PHE, WS and WH supervised the project. WS and WH designed the project. All authors read and approved the final manuscript.

Funding
The support of the Netherlands Organization for Scientific Research (NWO-CW VIDI grant 723.014.001 to WS.) and of the Dutch Cancer Society (KWF Grant # 11464 to WH) is gratefully acknowledged.

Availability of data and materials
The dataset(s) supporting the conclusions of this article is (are) included within the article (and its additional file(s)).

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 Groningen, The Netherlands. 2Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. 3Department of Radiology, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. 4Department of Surgery, Translational Surgical Oncology, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.

Received: 7 January 2022 Accepted: 10 February 2022

Published online: 03 March 2022

References

Altaf M, Membreno R, Cook B, Tolmachev V, Zegis BM. Pretargeted imaging and therapy. J Nucl Med. 2017;58:1553–9.
Bailly C, Bodet-Milin C, Rousseau C, Favier-Chauvet A, Kraeber-Bodéré F, Barbet J. Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharm Chem. 2017:2:6.
Conti M, Eriksson L. Physics of non-nucleotide positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8.
Dewulf J, Adhikari K, Vangestel C, Van Den Wyngaert T, Elvas F. Development of antibody immuno-PET/SPECT radiopharmaceuticals for imaging of oncological disorders—an update. Cancers. 2016;20(10):12.
Gill H, Marik J. Preparation of [18]F-labeled peptides using the copper(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition. Nat Protoc. 2011;6:1718–25.
Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunonotherapy. J Clin Oncol. 2006;24(5):823–34.
Guo H, Kommidi H, Maachani UB, Voronina JC, Zhang W, Magge RS, Ivanidze J, Wu AP, Souweidane MM, Aras O, Ting R. An [18]F-positron emitting fluorophore allows safe evaluation of small molecule distribution in the CSF, CSF fistulas, and CNS device placement. Mol Pharm. 2019;16(8):3636–46.
He Y, van Bommel PE, Sampionius DF, Bremer E, Helfrich W. A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Sci Rep. 2017;7(1):13301.
Heskamp S, Raavé R, Boerman O, Rijpkema M, Goncalves V, Denat F. 89Zr-immuno-positron emission tomography in oncology: state-of-the-art 89Zr radiochemistry. Bioconjugate Chem. 2017;28:2211–23.
Hnatowich DJ, Vizzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28(8):1294–302.
Jampel-Ivanovska E, Gautherot E, Hillairet de Boisferon M, Cohen M, Mil- haud G, Tartar A, Rostene W, Barbet J, Gruaz-Guyon A. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconj Chem. 1997;8:526–33.
Jaww WYS, Menike-van der Houwen van Oordt CW, Hoekstra OS, Hendriks NH, Vugts DJ, Zijlstra JM, Huismen MC, van Dongen GAMS. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharmacol. 2016;7:131.
Jennings LE, Long NJ. TiVo is better than one—probes for dual-modality molecular imaging. Chem Commun. 2009;25:3511–24.
Jordaan S, Chetty S, Mungra N, Koopmans I, van Bommel PE, Helfrich W, Barth S. CSPG4: a target for selective delivery of human cytolytic fusion proteins and TRAIL. Biomedicines. 2017;5(3):37.
Kageshita T, Nakamura T, Yamada M, Kuriya N, Aaro T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res. 1991;51(6):1726–32.
Kalbourn MR, Scott PJH, editors. Handbook of radiopharmaceuticals: methodology and applications. 2nd ed. New York: Wiley; 2021.
Kommidi H, Guo H, Chen N, Kim D, He B, Wu AP, Aras O, Ting R. An [18]F-positron-emitting, fluorescent, cerebrospinal fluid probe for imaging damage to the brain and spine. THERANOSTICS. 2017;7(9):2377–91.
Koopmans I, Hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 1990;50:3445–52.
Li ZZ, Wu Z, Chen K, Chin FT, Chen X. Click chemistry for [18]F-labeling of RGD peptides and microPET imaging of tumor integrin alphabeta3 expression. Bioconjug Chem. 2007;18:985–94.
Lumbroso B, Rispoli M. Practical handbook of fluorescein angiography. 1st ed. New Delhi: Jaypee Brothers Medical Publishers, 2014.
Lütje S, Rijpkema M, McBride B, Sharkey R, Goldenberg D, Franssen G, Eek A, Helfrich W, Oyen W, Boerman O. Pretargeted dual-modality SPECT/fluorescence imaging of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. J Nucl Med. 2014;55(1):1029.
Marquez BV, Lapo SE. Pretargeted immuno-PET: overcoming limitations of space and time. J Nucl Med. 2016;57(3):322–3.
McKnight BN, Viola-Vilegas NT. 89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Label Compd Radiopharm. 2018;61:727–38.
Meyer JP, Adumeau P, Lewis JS, Zeglis BM. Click chemistry and radiochemistry: the first 10 years. Bioconjugate Chem. 2016;27(12):2791–807.

Molema G, Jan Kroesen B, Helfrich W, Meijer DKf, de Leij LF. MH. The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy. J Control Release. 2000;64(1–3):229–39.

Rondon A, Degoul F. Antibody pretargeting based on bioorthogonal click chemistry for cancer imaging and targeted radionuclide therapy. Bioconjugate Chem. 2020;31(2):159–73.

Rossin R, Robillard MS. Pretargeted imaging using bioorthogonal chemistry in mice. Curr Opin Chem Biol. 2014;21:161–9.

Rondon R, Renart Verkerk P, van den Bosch SM, Vulders CRM, Verel I, Lub J, Robillard MS. In vivo chemistry for pretargeted tumor imaging in live mice. Angew Chem Int Ed. 2010;49:3375–8.

Ruszkowski M, Fogarasi M, Fritz B, Hnatowich DJ. Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl Med Biol. 1997;24:263–8.

Saunders MJ, Block E, Sorkin A, Waggoner AS, Bruchez MP. A bifunctional converter: fluorescein quenching scFv/fluorescein activating protein for photostability and improved signal to noise in fluorescence experiments. Bioconjugate Chem. 2014;25:1556–64.

Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CML, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WTA, Oyen WJG. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109:934–42.

Schwesinger F, Ros R, Strunz T, Anselmetti D, Guntherodt HJ, Honegger A, Jermutus L, Tiefenauer L, Plückthun A. Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates. PNAS. 2000;97(18):9972–7.

Sharkey RM, van Rij CM, Karacay H, Ross RA, Friemark C, terjo C, Cardillo TM, McBride WJ, Chang CH, Boerman OC, Goldenberg DM. A new tri-fab bispecific antibody for pretargeting trop-2—expressing epithelial cancers. J Nucl Med. 2012;53:325–32.

Sheikhbahaei S, Marcus CV, Fragomeni RS, Rowe SP, Javadi MS, Solnes LB. Whole-body 18 F-FDG PET and 18 F-FDG PET/CT in patients with suspected paraneoplastic syndrome: a systematic review and meta-analysis of diagnostic accuracy. J Nucl Med. 2017;58(7):1031–6.

Sirion U, Kim HJ, Lee JH, Seo JW, Lee BS, Lee SJ, Oh SJ, Chi DY. An efficient F-18 labeling method for PET study: Huisgen 1,3-dipolar cycloaddition of bioactive substances and F-18-labeled compounds. Tetrahedron Lett. 2007;48:3953–7.

Sun X, Xiao Z, Chen G, Han Z, Liu Y, Zhang C, Sun Y, Song Y, Wang K, Fang F, Wang X, Lin Y, Xu L, Shao L, Li J, Cheng Z, Gambhir SS, Shen B. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl Med. 2018;10(489):eaan8840.

Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, Walter F, Kunz WG, Münch af Rosenschild P, Jeraj R, Albert NL, Grosu AL, Niyyaz M, Bartenstein P, Belka C. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020;15:88.

van de Donk PP, Kist de Ruijter L, Lub de Hooge MN, Brouwers AH, van der Weken AJ, Oosting SF, Fehmarn RSN, de Groot DJA, de Vries EGE. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics. 2020;10(8):1708–18.

van de Watering FC, Rijpkema M, Robillard M, Oyen WJ, Boerman OC. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Front Med. 2014;1:44.

Weber PC, Ohlendorf DH, Wendoloski JI, Salemm FR. Structural origins of high-affinity biotin binding to streptavidin. Science. 1989;243:85–8.

Yu S, Li A, Liu Q, Yuan X, Hu H, Jiao D, Pestell RG, Han X, Wu K. Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol. 2017;10:155.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.